Entrada Therapeutics, Inc. – NASDAQ:TRDA
Entrada Therapeutics stock price today
$5.5
-11.91
-68.41%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
Entrada Therapeutics stock price monthly change
+1.52%
month
Entrada Therapeutics stock price quarterly change
+1.52%
quarter
Entrada Therapeutics stock price yearly change
+3.08%
year
Entrada Therapeutics key metrics
Market Cap | 640.25M |
Enterprise value | 453.62M |
P/E | -5.07 |
EV/Sales | N/A |
EV/EBITDA | -5.04 |
Price/Sales | N/A |
Price/Book | 2.22 |
PEG ratio | -0.21 |
EPS | 0.7 |
Revenue | 162.87M |
EBITDA | 25.40M |
Income | 23.48M |
Revenue Q/Q | 134.04% |
Revenue Y/Y | 544.78% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | 15.6% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEntrada Therapeutics stock price history
Entrada Therapeutics stock forecast
Entrada Therapeutics financial statements
Average Price Target
$20
Potential upside: 263.63%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 18.17M | -25.92M | -142.7% |
|---|---|---|---|
| Sep 2023 | 43.73M | 35.46M | 81.08% |
| Dec 2023 | 41.84M | -9.54M | -22.81% |
| Mar 2024 | 59.12M | 23.49M | 39.74% |
| 2024-03-13 | -0.07 | -0.29 |
|---|---|---|
| 2024-05-07 | -0.59 | 0.68 |
| Jun 2023 | 493983000 | 287.07M | 58.11% |
|---|---|---|---|
| Sep 2023 | 485033000 | 238.37M | 49.15% |
| Dec 2023 | 469192000 | 226.83M | 48.35% |
| Mar 2024 | 510844000 | 241.47M | 47.27% |
| Jun 2023 | -35.09M | -113.25M | 443K |
|---|---|---|---|
| Sep 2023 | -24.49M | -3.73M | 368K |
| Dec 2023 | -4.01M | 19.04M | 690K |
| Mar 2024 | -25.51M | 26.14M | 206K |
Entrada Therapeutics alternative data
| Aug 2023 | 130 |
|---|---|
| Sep 2023 | 131 |
| Oct 2023 | 131 |
| Nov 2023 | 131 |
| Dec 2023 | 150 |
| Jan 2024 | 150 |
| Feb 2024 | 150 |
| Mar 2024 | 159 |
| Apr 2024 | 159 |
| May 2024 | 159 |
| Jun 2024 | 160 |
| Jul 2024 | 160 |
Entrada Therapeutics other data
24.03%
-54.94%
of TRDA is owned by hedge funds
25
-21
7.51M
-17.19M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 1000 |
| Feb 2024 | 0 | 1000 |
| Mar 2024 | 13292 | 5912 |
| Apr 2024 | 2600 | 0 |
| May 2024 | 29476 | 21980 |
| Jun 2024 | 3367003 | 1000 |
| Jul 2024 | 0 | 4896 |
| Aug 2024 | 0 | 27097 |
| Sep 2024 | 0 | 9587 |
| Oct 2024 | 0 | 600 |
| Nov 2024 | 0 | 32065 |
| Dec 2024 | 0 | 110235 |
-
What's the price of Entrada Therapeutics stock today?
One share of Entrada Therapeutics stock can currently be purchased for approximately $5.5.
-
When is Entrada Therapeutics's next earnings date?
Unfortunately, Entrada Therapeutics's (TRDA) next earnings date is currently unknown.
-
Does Entrada Therapeutics pay dividends?
No, Entrada Therapeutics does not pay dividends.
-
How much money does Entrada Therapeutics make?
Entrada Therapeutics has a market capitalization of 640.25M. Entrada Therapeutics made a loss 6.69M US dollars in net income (profit) last year or $0.68 on an earnings per share basis.
-
What is Entrada Therapeutics's stock symbol?
Entrada Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TRDA".
-
What is Entrada Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Entrada Therapeutics?
Shares of Entrada Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Entrada Therapeutics have?
As Jul 2024, Entrada Therapeutics employs 160 workers, which is 1% more then previous quarter.
-
When Entrada Therapeutics went public?
Entrada Therapeutics, Inc. is publicly traded company for more then 3 years since IPO on 29 Oct 2021.
-
What is Entrada Therapeutics's official website?
The official website for Entrada Therapeutics is entradatx.com.
-
Where are Entrada Therapeutics's headquarters?
Entrada Therapeutics is headquartered at 6 Tide Street, Boston, MA.
-
How can i contact Entrada Therapeutics?
Entrada Therapeutics's mailing address is 6 Tide Street, Boston, MA and company can be reached via phone at 857 520 9158.
-
What is Entrada Therapeutics stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for Entrada Therapeutics in the last 12 months, the avarage price target is $20. The average price target represents a 263.63% change from the last price of $5.5.
Entrada Therapeutics company profile:
Entrada Therapeutics, Inc.
entradatx.comExchange:
NASDAQ
Full time employees:
177
Industry:
Biotechnology
Sector:
Healthcare
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
6 Tide Street
Boston, MA 02210
Boston, MA 02210
CIK: 0001689375
ISIN: US29384C1080
CUSIP: 29384C108
